Negative in Ames, in vitro chromosome aberration (human lymphocytes) and rat micronucleus assays
“Mavorixafor (free base) was not mutagenic in the Ames assay (bacterial reverse mutation assay), or clastogenic in vitro (chromosome aberration assay in human peripheral lymphocytes) or in vivo (rat bone marrow micronucleus assay).”
“Carcinogenicity studies with mavorixafor have not been conducted. There was a prior agreement with the Applicant regarding the need for postmarketing requirement (PMR) studies to assess the carcinogenicity potential of mavorixafor.”
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
No dedicated fertility, EFD or pre/postnatal studies; literature-based weight-of-evidence assessment
“No dedicated fertility and early embryonic development, definitive embryo-fetal development, or pre- and post-natal development toxicity studies were conducted with mavorixafor. The Applicant provided a weight-of-evidence assessment informing potential reproductive risks associated with mavorixafor treatment.”
“Mavorixafor (free base) was not mutagenic in the Ames assay (bacterial reverse mutation assay), or clastogenic in vitro (chromosome aberration assay in human peripheral lymphocytes) or in vivo (rat bone marrow micronucleus assay).”
“Mavorixafor (free base) was not mutagenic in the Ames assay (bacterial reverse mutation assay), or clastogenic in vitro (chromosome aberration assay in human peripheral lymphocytes) or in vivo (rat bone marrow micronucleus assay).”
“Mavorixafor (free base) was not mutagenic in the Ames assay (bacterial reverse mutation assay), or clastogenic in vitro (chromosome aberration assay in human peripheral lymphocytes) or in vivo (rat bone marrow micronucleus assay).”
“PMR 3: Conduct a 26-week GLP carcinogenicity study by oral gavage administration in Tg.RasH2 mice to assess the carcinogenic potential from chronic exposure to mavorixafor.”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative